Pharmaceutical Industry Reports Newborn Screening Market | Seite 2

REPORT DESCRIPTION
Newborn Screening Market – Overview
Increasing number of newborn screenings, owing to rising awareness among parents and governments is expected
to drive the newborn screening market growth. According to the Centers for Disease Control and Prevention
(CDC) 2017, four million infants in the U.S. are routinely screened, using a few drops of blood from their heel,
for certain endocrine, genetic, and metabolic disorders. The infants are also tested for hearing loss and Critical
Congenital Heart Defects (CCHDs) prior to discharge from a hospital or birth center.
Furthermore, increasing incidence of hospital acquired diseases create an acute need for newborn screening. For
instance, according to the Center for Disease Control and Prevention (CDC), in 2011, around one in every 25
infants was infected with at least one hospital acquired infections.
Government initiatives to support screening of newborns is also a major factor driving the newborn screening
market. For instance, CDC is working to harness the latest advances in science and technology so that more
disorders can be identified accurately and treated quickly. In 2005, CDC established the Newborn Screening
Translation Research Initiative (NSTRI) with the CDC Foundation. NSTRI works with corporate, academic, and
foundation partners to assure the quality of research methods during both pilot studies and routine screening.